Home Cart Sign in  
Chemical Structure| 1405-97-6 Chemical Structure| 1405-97-6

Structure of Gramicidin
CAS No.: 1405-97-6

Chemical Structure| 1405-97-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Gramicidin is a polypeptide antibiotic mixture of gramicidin A, gramicidin B, and gramicidin C originally isolated from B. brevis.

Synonyms: Gramicidin D

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Gramicidin

CAS No. :1405-97-6
Formula : C99H140N20O17
M.W : 1882.29
SMILES Code : CC(CC(/N=C(O)/C(/N=C(O)/C/N=C(O)/C(/N=C/O)C(C)C)C)/C(O)=N/C(/C(O)=N/C(/C(O)=N/C(/C(O)=N/C(/C(O)=N/C(/C(O)=N/C(/C(O)=N/C(/C(O)=N/C(/C(O)=N/C(/C(O)=N/C(/C(O)=N/C(/C(O)=N/CCO)CC1=CNC2=CC=CC=C12)CC(C)C)CC3=CNC4=CC=CC=C34)CC(C)C)CC5=CNC6=CC=CC=C56)CC(C)C)CC7=CNC8=CC=CC=C78)C(C)C)C(C)C)C(C)C)C)C
Synonyms :
Gramicidin D
MDL No. :MFCD00131232

Safety of Gramicidin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
mouse cortical pyramidal neurons 80 mg/mL 10 minutes To measure the equilibrium potential and driving force for synaptic GABA-A receptors Neuron. 2023 Nov 15;111(22):3531-3540. e6
NIH3T3 cells 1 μM 30 minutes Gramicidin A treatment dissipates plasma membrane potential by forming cation-permeable channels, significantly reducing PAC-NAE uptake EMBO J. 2020 Nov 2;39(21):e101767
4T1 cells 10 µM Permeabilization of cell membranes with gramicidin-A led to a titratable increase of [Na+]i and a Na+-dependent increase in glycolytic flux Cancer Metab. 2024 May 24;12(1):15
MDA-MB-231 cells 10 µM Permeabilization of cell membranes with gramicidin-A led to a titratable increase of [Na+]i and a Na+-dependent increase in glycolytic flux Cancer Metab. 2024 May 24;12(1):15
HeLa cells 0.1 μM, 0.5 μM, 2.5 μM 25 min, 1 h, 24 h Gramicidin causes immediate intracellular sodium accumulation and osmotic swelling; however, within 24 h, swelling gives way to shrinkage, whose extent depends on gramicidin concentration. Cells. 2021 Dec 14;10(12):3532
human red blood cells (hRBCs) 128 μM 1 hour Assessed hemolytic activity, showing no hemolytic activity at the highest concentration Int J Mol Sci. 2019 Nov 25;20(23):5904
RAW264.7 cells 128 μM 24 hours Assessed cytotoxicity, showing 70% cell survival at the highest concentration Int J Mol Sci. 2019 Nov 25;20(23):5904
Rabbit red blood cells 160 nM (HC10) Evaluation of the hemolytic activity of Gramicidin A against rabbit red blood cells, with an HC10 value of 160 nM. Nat Commun. 2020 Oct 1;11(1):4935
P388 mouse leukemia cells 5.8 nM (IC50) Evaluation of the cytotoxicity of Gramicidin A against P388 mouse leukemia cells, with an IC50 value of 5.8 nM. Nat Commun. 2020 Oct 1;11(1):4935

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Drosophila Drosophila wing discs In vitro culture treatment 1 μM Single treatment for 30 minutes Gramicidin A disrupts cellular uptake of N-acylethanolamides by dissipating plasma membrane potential, thereby affecting the Hedgehog signaling pathway EMBO J. 2020 Nov 2;39(21):e101767
BALB/c nude mice Colorectal cancer xenograft model Intratumoral injection 8 nM Gramicidin significantly inhibited tumor growth and reduced Ki-67 expression. Cell Death Dis. 2024 Dec 18;15(12):896
ICR mice Allergic dermatitis model Topical administration 2% (w/v) Single dose, evaluated after 24 hours Assessed anti-inflammatory effects, showing significant reduction in ear swelling and inflammatory cytokine expression Int J Mol Sci. 2019 Nov 25;20(23):5904

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01608880 Mastectomy Flap Necrosis Not Applicable Completed - Canada, British Columbia ... More >> Mount Saint Joseph Hospital Vancouver, British Columbia, Canada, V5T 3N4 Vancouver General Hospital Vancouver, British Columbia, Canada, V5Z 1M9 University of British Columbia Hospital Vancouver, British Columbia, Canada, V6T 2B5 Less <<
NCT03715387 Edema Face Phase 2 Phase 3 Recruiting July 1, 2019 Canada, British Columbia ... More >> Vancouver Plastic Surgery Center Recruiting Vancouver, British Columbia, Canada, V5Z 4J7 Contact: Richard Warren, MD    604-876-1774       Contact: Tracy Stuby Less <<
NCT01950598 Corneal Blindness ... More >> Boston Keratoprosthesis Type I Candidate Less << Not Applicable Active, not recruiting January 2020 Canada, Quebec ... More >> Centre Hospitalier de l'Université de Montréal Montréal, Quebec, Canada, H2L 4M1 Less <<
NCT00990392 Blood Stream Infections ... More >> Skin Diseases, Infectious Less << Not Applicable Withdrawn(Change of practice t... More >>o antibiotic impregnated catheters and large study published showing their efficacy. Made topical antibiotics obselete.) Less << - Canada, British Columbia ... More >> Royal Columbian Hospital New Westminster, British Columbia, Canada, V3L 1A1 Less <<
NCT01809483 Erosion; Cornea, Traumatic Phase 3 Completed - Indonesia ... More >> Depatment of Ophthalmolohy, Medical Faculty, Udayana University / Sanglah Public General Hospital Denpasar, Bali, Indonesia, 80114 Less <<
NCT00534391 Hordeolum Phase 3 Unknown December 2008 Thailand ... More >> Department of Ophthalmology, Chulalongkorn University Recruiting Bangkok, Thailand, 10330 Contact: Parima Hirunwiwatkul, MD    662-2564142 ext 205    parima.H@chula.ac.th    Contact: Puangphet Chalermphanich, MD    662-256-4142 ext 207    puangphet_c@yahoo.com    Principal Investigator: Parima Hirunwiwatkul, MD Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

0.53mL

0.11mL

0.05mL

2.66mL

0.53mL

0.27mL

5.31mL

1.06mL

0.53mL

 

Historical Records

Categories